A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : SERMs / selective ER modulators

[Related PubMed/MEDLINE]
Total Number of Papers: 42
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   SERMs  (>> Co-occurring Abbreviation)
Long Form:   selective ER modulators
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Current and emerging medical therapeutic agents for idiopathic male infertility. FSH
2019 Endocrine therapy in endometrial cancer: An old dog with new tricks. AIs, EC, ER, PR
2019 Role of SUMOylation in differential ERalpha transcriptional repression by tamoxifen and fulvestrant in breast cancer cells. AEs, BC, ERalpha, TAM
2018 Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine. ADT, AR, CRPC, EAB, PC
2017 Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer. AIs, CSCs, ER, SERDs
2017 Exploring the Structural Compliancy versus Specificity of the Estrogen Receptor Using Isomeric Three-Dimensional Ligands. ERs
2017 Phytochemicals Targeting Estrogen Receptors: Beneficial Rather Than Adverse Effects? ER
2017 TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-kappaB Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response. GWAS, NF-kappaB, SNPs, TLRs
2017 The small heat shock protein B8 (HSPB8) modulates proliferation and migration of breast cancer cells. BC, ER, HSPB8
10  2016 SERMs have substance-specific effects on bone, and these effects are mediated via ERalphaAF-1 in female mice. AF, BZA, ER, LAS, RAL, WT
11  2015 Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association. ERalpha
12  2015 Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader. ESR1, SERD
13  2014 Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women. ER, TSECs
14  2014 The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators. ER, FDA
15  2013 Pharmacogenomics of endocrine therapy in breast cancer. AIs, ER, GWAS
16  2012 Mechanisms of the hepatoprotective effects of tamoxifen against drug-induced and chemical-induced acute liver injuries. ER, Mmd-2, siMmd2, TA, TAM
17  2012 Tamoxifen downregulation of miR-451 increases 14-3-3zeta and promotes breast cancer cell survival and endocrine resistance. ER, miR
18  2011 Differential vasoactive effects of oestrogen, oestrogen receptor agonists and selective oestrogen receptor modulators in rat middle cerebral artery. ER, MCA
19  2008 Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors. ER, NAT1
20  2007 Differential activation of wild-type estrogen receptor alpha and C-terminal deletion mutants by estrogens, antiestrogens and xenoestrogens in breast cancer cells. AF-2, DES, ERalpha, EREs
21  2007 Signaling by estrogens. ER
22  2006 Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylation. AF-1, ERalpha, ICI-780, Ser118
23  2006 Aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha in MCF-7 breast cancer cells. 3-MC, AhR, ER, SAhRMs, TCDD
24  2006 Biology of estrogens in skin: implications for skin aging. ERs, HRT
25  2006 Models of hormone resistance in vitro and in vivo. ER
26  2005 ERbeta-selective estrogen receptor modulators produce antianxiety behavior when administered systemically to ovariectomized rats. DPN, ER, PPT
27  2005 Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. ER
28  2005 Recruitment of histone deacetylase 4 to the N-terminal region of estrogen receptor alpha. ERalpha, HDAC4
29  2004 Antidepressant effects of ERbeta-selective estrogen receptor modulators in the forced swim test. DPN, ER, PPT
30  2004 Nuclear receptors in disease: the oestrogen receptors. ERKO, SNPs
31  2004 Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins. 4-HT, ERalpha
32  2004 Therapeutic targeting in the estrogen receptor hormonal pathway. ERs
33  2003 Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. ER
34  2003 Molecular sensors of estrogen receptor conformations and dynamics. ER, LBD
35  2003 Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. COX-2, ER, MAPK, TKIs
36  2002 Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (Review). AhR, ER, SAhRMs, TCDD
37  2002 Problems for risk assessment of endocrine-active estrogenic compounds. BPA, ER, ER-AF1
38  2002 Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial. DM, PL, RLX
39  2002 Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. ER
40  2001 Development of an ER action indicator mouse for the study of estrogens, selective ER modulators (SERMs), and Xenobiotics. ERIN
41  2001 Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. AIs, ERs
42  2001 Identification of new triarylethylene oxyalkanoic acid analogues as bone selective estrogen mimetics. ER